Glucagon-like peptide-1 receptor agonists tied to lower risk for early-onset colorectal cancer

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a study presented at the annual meeting of the American College of Gastroenterology, held from Oct. 25 to 30 in Philadelphia.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup